-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, PFT4TU79PGgZBAfmEcEx62ie7aq5qUleOtoIHVZaHu9RLJv4V0pXbhlnVagrxTOE BTVoUYKKiTwuSTjePCnsjg== 0001004878-97-000089.txt : 19971120 0001004878-97-000089.hdr.sgml : 19971120 ACCESSION NUMBER: 0001004878-97-000089 CONFORMED SUBMISSION TYPE: SC 13E4 PUBLIC DOCUMENT COUNT: 3 FILED AS OF DATE: 19971119 SROS: NASD SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: CEL SCI CORP CENTRAL INDEX KEY: 0000725363 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 840916344 STATE OF INCORPORATION: CO FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: SC 13E4 SEC ACT: SEC FILE NUMBER: 005-35386 FILM NUMBER: 97724299 BUSINESS ADDRESS: STREET 1: 66 CANAL CENTER PLZ STE 510 CITY: ALEXANDRIA STATE: VA ZIP: 22314 BUSINESS PHONE: 7035495293 MAIL ADDRESS: STREET 1: 66 CANAL CENTER PLAZA SUITE 510 CITY: ALEXANDRIA STATE: VA ZIP: 22314 FORMER COMPANY: FORMER CONFORMED NAME: INTERLEUKIN 2 INC DATE OF NAME CHANGE: 19880317 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: CEL SCI CORP CENTRAL INDEX KEY: 0000725363 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 840916344 STATE OF INCORPORATION: CO FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: SC 13E4 BUSINESS ADDRESS: STREET 1: 66 CANAL CENTER PLZ STE 510 CITY: ALEXANDRIA STATE: VA ZIP: 22314 BUSINESS PHONE: 7035495293 MAIL ADDRESS: STREET 1: 66 CANAL CENTER PLAZA SUITE 510 CITY: ALEXANDRIA STATE: VA ZIP: 22314 FORMER COMPANY: FORMER CONFORMED NAME: INTERLEUKIN 2 INC DATE OF NAME CHANGE: 19880317 SC 13E4 1 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13E-4 Issuer Tender Offer Statement Pursuant to Section l3(e)(l) of the Securities Exchange Act of l934 (Amendment No. _) CEL-SCI CORPORATION (Name of Issuer) CEL-SCI CORPORATION (Name of Person(s) Filing Statement) Common Stock Purchase Warrants (Title of Class of Securities) 150-837-128 (CUSIP Number of Class of Securities) William T. Hart, Esq. Hart & Trinen l624 Washington Street Denver, Colorado 80203 303-839-006l (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications on Behalf of the Person(s) Filing Statement) November 14, l997 (Date Tender Offer First Published, Sent or Given to Security Holders) Calculation of Filing Fee: ---------------------------------------------- ( ) ) ( Transaction ) Amount of Filing Fee ) ( Valuation* ) $5l7.50 ) ( ) ) ---------------------------------------------- The valuation set forth above is based upon the market price of the Warrants, assuming all Warrants are tendered pursuant to this offering. *Set forth the amount on which the filing fee is calculated and state how it was determined. [X] Check box if any part of the fee is offset as provided by Rule 0-ll(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration state- ment number, or the Form or Schedule and the date of its filing. Amounts Previously Paid: $1,317 Form or Registration Nos.: 333-31489 Filing Party: CEL-SCI Corporation Dates Filed: August 4, l997 Item l. Security and Issuer (a) The name of the issuer is CEL-SCI Corporation. The address of its principal executive office is 66 Canal Center Plaza, Suite 510, Alexandria, Virginia 22314. (b) This offer relates to the issuer's Common Stock Purchase Warrants (the "Warrants"), of which 5,175,000 Warrants are outstanding as of the date hereof. A Warrant holder who tenders five Warrants and $6.00 in cash will receive one share of the issuer's common stock (the "Common Stock") and one Series A Warrant. Warrants may be acquired from officers, directors or affiliates of the issuer. (c) Incorporated by reference to that portion of the issuer's Registration Statement on Form S-3, SEC File No. 333-31489 (the "Registration Statement") captioned "Market for the Company's Common Stock." (d) Not applicable. Item 2. Source and Amount of Funds or Other Consideration. (a) See Item l(b) above. (b) Not applicable. Item 3. Purposes of the Tender Offer and Plans or Proposals of the Issuer or Affiliate. Incorporated by reference to those portions of the Registration Statement captioned "Plan of Distribution - Exchange Offer." Item 4. Interest in Securities of the Issuer. None. Item 5. Contracts, Arrangements, Understandings or Relationships with Respect to the Issuer's Securities. None. Item 6. Persons Retained, Employed or to be Compensated. None. Item 7. Financial Information. (a) Incorporated by reference to those portions of the Registration Statement captioned "Prospectus Summary". (b) Not applicable. Item 8. Additional Information. None. Item 9. Material to be Filed as Exhibits. (a) Letter of Transmittal. See also (e) below. (b) None. (c) None. (d) None. (e) Prospectus filed as part of a Registration Statement on Form S-3, Registration Number 333-31489. (f) None. Signature After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. CEL-SCI CORPORATION November 17, 1997 By: /s/ Geert R. Kersten -------------------- Geert R. Kersten Chief Executive Officer SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13E-4 Issuer Tender Offer Statement Pursuant to Section l3(e)(l) of the Securities Exchange Act of l934 CEL-SCI CORPORATION EXHIBITS EX-99.A 2 LETTER OF TRANSMITTAL IMPORTANT: EXCHANGE OFFER BEGINS JANUARY 9, 1998 AND EXPIRES 6:00 P.M. DENVER, COLORADO TIME ON FEBRUARY 6, 1998 UNLESS EXTENDED LETTER OF TRANSMITTAL TO ACCOMPANY COMMON STOCK PURCHASE WARRANTS AND CASH TENDERED PURSUANT TO THE EXCHANGE OFFER OF CEL-SCI CORPORATION The Warrant Agent: AMERICAN SECURITIES TRANSFER & TRUST, INC. By Mail: By Facsimile: By Hand: 938 Quail Street (303) 234-5340 938 Quail Street Suite l0l Suite l0l Lakewood, Colorado 802l5 Lakewood, Colorado 802l5 Wire transfer instructions: Union Bank & Trust 100 Broadway Denver, Co. 80209 (303) 744-3221 ABA # 102000908 Credit Account # 85-02961 The instructions accompanying this Letter of Transmittal should be read carefully before this Letter of Transmittal is completed. The undersigned hereby tenders to CEL-SCI Corporation, (the "Company"), Common Stock Purchase Warrants (the "Warrants"), together with payment in the amount of $6.00 for every five Warrants tendered in exchange for (i) one share of the Company's Common Stock, and (ii) one Series A Warrant. Such Warrants and cash are tendered in accordance with the terms and conditions of the Exchange Offer as set forth in the Company's Prospectus dated November 14, l997 Every five Warrants tendered pursuant to the Exchange Offer must be accompanied by payment in the amount of $6.00. Payment may be made to the Warrant Agent by cash, wire transfer, bank cashier's check, postal money order or personal check. In the case of payment by personal check, the shares of common stock and Series A Warrants will not be issued to the tendering Warrantholder until the check has cleared the Warrantholder's bank. The name and address of the registered owner(s) have been printed below exactly as they appear on the certificate(s) representing Warrants tendered hereby. The certificate(s) and the number of Warrants that the undersigned wishes to tender are indicated in the appropriate boxes. The undersigned represents that he or she has full authority to sell and to transfer the tendered Warrants and that the Company will acquire good title thereto free and clear of all liens, claims and encumbrances. The undersigned will, upon request, execute any additional documents necessary to complete the sale and transfer of the tendered Warrants. All authority conferred or agreed to be conferred in this Letter of Transmittal shall be binding upon the successors, assigns, heirs, executors, administrators and legal representatives of the undersigned and shall not be affected by and shall survive the death or incapacity of the undersigned. The undersigned hereby irrevocaby constitutes the Warrant Agent as attorney with full power of substitution to deliver the tendered Warrants and the required payment together with all accompanying evidences of authority to or upon the order of the Company and to cause the tendered Warrants to be cancelled on the books of the Company. Please issue and deliver the certificates for the shares of Common Stock and Series A Warrants to the undersigned at the address specified below unless otherwise indicated under Special Instructions. DESCRIPTION OF WARRANTS TENDERED Certificates Enclosed ----------------------------------------------- Number of Warrant Warrants Number of Print Name and Address of Certificate Represented By Warrants Registered Owner(s) Number Certificate Tendered - ------------------------- ----------- -------------- --------- SIGN HERE - ------------------------------------------------------------------------------- - ------------------------------------------------------------------------------- Signature(s) of Warrantholder(s) Signature Guaranteed:__________________________________________________________ Necessary only in cases specified in Instruction l. The signature(s) must be guaranteed by an elgible guarantor institution (Banks, Stockbrokers, Savings and Loan Associations and Credit Unions with membership in an approved signature guarantee Medallion Program) pursuant to S.E.C. Rule 17Ad-15. Must be signed by registered holder(s) exactly as name(s) appear(s) on warrant certificate(s) or by person authorized to become registered holder(s) by certificates and documents transmitted. If signature is by executor, administrator, trustee, guardian, attorney, agent or other person acting in a fiduciary or representative capacity, please set forth full title. See Instructions. Dated:_________________________________________________________________________ Name(s):_______________________________________________________________________ - ------------------------------------------------------------------------------- (Please Print) Capacity:______________________________________________________________________ Address:_______________________________________________________________________ - ------------------------------------------------------------------------------- (Include Zip Code) Telephone Number:______________________________________________________________ (Include Area Code) Tax Identification or Social Security No.:_____________________________________ SPECIAL INSTRUCTIONS To be completed ONLY if certificates for the shares of Common Stock and Series A Warrants are to be issued in the name of and sent to someone other than the undersigned. Issue Certificates To: Name:__________________________________________________________________________ (Please Print) Address:_______________________________________________________________________ - ------------------------------------------------------------------------------- (Include Zipe Code) Telephone No.:_________________________________________________________________ Tax Identification or Social Security No.:_____________________________________ GUARANTEE OF DELIVERY Use Only if Certificates Are Not Tendered with this Letter of Transmittal (See Instruction 2) The undersigned: ___ a member of a national securities exchange ___ a member of the NASD ___ a commercial bank or trust company having an office in the United States guarantees that the Warrants indicated in the box on page l as tendered are held for its own account, or for the account(s) of others who have authorized this tender, and guarantees to deliver to the Warrant Agent in proper form for transfer, certificates for the Warrants tendered by this Letter of Transmittal within three (3) business days after expiration of the Exchange Offer and confirms that the tender of such Warrants is in compliance with Rule l4e-4 promulgated under the Securities Exchange act of l934. Firm Name: Address:_______________________________________________________________________ - ------------------------------------------------------------------------------- Authorized Signature:__________________________________________________________ Area Code and Telephone Number:________________________________________________ Date:__________________________________________________________________________ INSTRUCTIONS Forming Part of the Terms and Conditions of the Exchange Offer l. Delivery of Letter of Transmittal and Certificates; Signature Guarantees. Tenders made by means of this Letter of Transmittal, or a facsimile thereof, signed by the registered holder(s) or the persons(s) authorized to become a registered holder of the tendered Warrants, must be received by the Warrant Agent prior to 6:00 P.M., Denver, Colorado time, on February 6, 1998 (the "Expiration Date"), unless the Offer is extended. If Warrants are tendered by a registered holder who has completed the box entitled "Special Instructions," signatures on the Letter of Transmittal must be guaranteed by an elgible guarantor institution (Banks, Stockbrokers, Savings and Loan Associations and Credit Unions with membership in an approved signature guarantee Medallion Program), pursuant to S.E.C. Rule 17Ad-15, unless tendered on behalf of such member, commercial bank or trust company. If certificates are registered in the name of a person other than the signer of the Letter of Transmittal, the certificate(s) must be duly endorsed, or accompanied by appropriate powers signed, by the registered holder with the signature endorsement or appropriate power guaranteed thereon and on the Letter of Transmittal as provided above. If the Letter of Transmittal is executed by an officer on behalf of a corporation or by an executor, administrator, trustee, guardian, attorney, agent or other person acting in a fiduciary or a representative capacity, proper documentary evidence must be furnished of the authority of the person executing the same. If the tendered certificates are owned of record by two or more joint owners, all such owners must sign the Letter of Transmittal. Questions regarding such evidence of authority may be referred to the Warrant Agent. 2. Guarantee of Delivery. Prior to the Expiration Date, tenders may be made without the concurrent deposit of warrant certificates if such tenders are made by or through members of a national securites exchange or the NASD or by commercial banks or trust companies having an office in the United States (an "Eligible Institution") and are accompanied by the applicable payment. In such cases, the Letter of Transmittal and the applicable payment must be received prior to the Expiration Date by the Warrant Agent and the Guarantee of delivery contained in the Letter of Transmittal must be executed by such Eligible Institution. In addition, the certificates tendered thereby must be received by the Warrant Agent no later than five (5) business days after the Expiration Date. The Company expressly reserves the right to extend the Expiration Date by giving oral or written notice of such extension to the Warrant Agent and by causing written notice of such extension to be mailed to all Warrant holders of record, and to be published in The Wall Street Journal, the New York Times or other newspapers of national circulation selected by the Company. If a Warrant holder desires to tender Warrants pursuant to the Offer and time will not permit his or her Letter of Transmittal to reach the Warrant Agent prior to the Expiration Date, his or her tender may be effected if, prior to the Expiration Date, the Warrant Agent has received the applicable payment and a telegram or letter from an Eligible Institution setting forth the name of the Warrant holder, the number of Warrants tendered and a statement that the tender is being made thereby and guaranteeing that the warrant certificates, together with the Letter of Transmittal, and any other required documents, will be received by the Warrant Agent no later than five (5) business days after the Expiration Date and representing that the Warrant holder on whose behalf the tender is being made is deemed to own the Warrants being tendered within the meaning of Rule l4e-4 promulgated under the Securities Exchange Act of l934, as amended. The exchange, in any event, for Warrants tendered pursuant to the Offer will be made only after the timely receipt by the Warrant Agent of certificates and payment therefor, and any other required documents. 3. Partial Tenders. If fewer than all the Warrants evidenced by any certificate submitted are to be tendered, fill in the Number of Warrants which are to be tendered in the box entitled "Number of Warrants Tendered." A new certificate for the remainder of the Warrants which were evidenced by your old certificate(s) will be sent to you, unless otherwise provided in the appropriate box on this Letter of Transmittal, as soon as practicable after the expiration of the Offer. All Warrants represented by certificates listed are deemed to have been tendered unless otherwise indicated. 4. Methods of Delivery of Letter of Transmittal and Certificates. The method of delivery of this Letter of Transmittal, the warrant certificates, cash payment and any other required documents is at the option and risk of the Warrant holder, but, except as otherwise provided in Instruction 2 above, the delivery will be deemed made only when actually received by the Warrant Agent. If such delivery is by mail, registered mail with return receipt requested, properly insured, is recommended. 5. Payments. The applicable payments to accompany the Warrants tendered may be made by cash, wire transfer, bank cashier's check, personal check, or postal money order or personal check, payable in United States dollars to the order of American Securities Transfer & Trust, Inc., as Warrant Agent for the Company. If payment is made by personal check the shares of common stock and Series A Warrants will not be issued to the tendering Warrant holder until the check has cleared the Warrant holder's bank. 6. No Conditional Tenders. No alternative, conditional, irregular or contingent tenders will be accepted. 7. Multiple Registrations. If a Warrant holder's Warrants are registered differently on several certificates, it will be necessary for the Warrant holder to complete, sign and submit as many separate Letters of Transmittal as there are different registrations of Warrants. 8. Inadequate Space. If the space provided on page l of this Letter of Transmittal is inadequate, the certificate numbers and number of Warrants should be listed on a separate signed schedule attached to this document. 9. Withdrawal Rights. Tenders of Warrants and payments may be withdrawn at any time prior to the termination of this Offering, and if not yet accepted for exchange after March 7, 1998. For withdrawal to be effective, a written, or facsimile transmission notice of withdrawal must be timely received by the Warrant Agent at the address as set forth above. Such notice of withdrawal must set forth the name of the tendering Warrant holder, the name of the registered holder if different from that of the Warrant holder, the number of Warrants (and, if available, the certificate numbers) and the amount of the payment to be withdrawn. All questions as to the validity (including time of receipt) of notices of withdrawal will be determined by the Company, whose determination shall be final and binding. All Warrants and payments withdrawn in the manner specified above will not be considered to have been duly tendered. 10. Waiver of Conditions. The Company reserves the absolute right to waive any of the specified conditions in the Offer in the case of any Warrants tendered. l1. Requests for Assistance or Additional Copies. Questions and requests for assistance or additional copies of the Prospectus and the Letter of Transmittal may be directed to the Warrant Agent or to the Company as set forth below: Warrant Agent: Company: American Securities Transfer & Trust, Inc. CEL-SCI Corporation 938 Quail Street, Suite l0l 66 Canal Center Plaza, Suite 510 Lakewood, Colorado 802l5 Alexandria, Virginia 22314 Telephone: (303) 234-5300 Telephone: (703) 549-5293 Telecopy: (303) 234-5340 Telecopy: (703) 549-6269 EX-99.E 3 PROSPECTUS FILED AS PART OF FORM S-3 424(b)(2) Commission File #333-31489 PROSPECTUS CEL-SCI CORPORATION This Prospectus relates to the sale by the Company of upon to 1,035,000 shares of Common Stock which are issuable upon the exercise of 5,175,000 Warrants which were issued in connection with the Company's February 1992 public offering of Units. Each Unit sold in such offering consisted of five shares of Common Stock and five Common Stock Purchase Warrants (the "Warrants"). The Warrants are exercisable at any time prior to February 7, 1998 (the "Warrant Expiration Date"). The terms of the Warrants presently provide that every five Warrants allow the holder to purchase one share of the Company's Common Stock at a price of $6.00 per share. The Company, upon 30-days notice, may accelerate the expiration date of the Warrants, provided, however, that at the time the Company gives such notice of acceleration (1) the Company has in effect a current registration statement covering the shares of Common Stock issuable upon the exercise of the Warrants and (2) at any time during the 30 day period preceding such notice, the average closing bid price of the Company's Common Stock has been at least 20% higher than the Warrant exercise price for l5 consecutive trading days. If the expiration date is accelerated, all Warrants not exercised within the 30-day period will expire. Notwithstanding the above, at any time between January 9, l998 and February 6, 1998 every five Warrants will allow the holder to purchase, for $6.00, one share of the Company's common stock and one Series A Warrant. Each Series A Warrant entitles the holder to purchase one share of the Company's Common Stock at a price of $18.00 per share at any time prior to February 7, 2000. The foregoing offer (the "Exchange Offer"), unless extended by the Company, will expire on February 6, 1998 (the "Expiration Date"). The expiration date of the Series A Warrants may be accelerated under certain conditions. The shares of Common Stock and Series A Warrants will be separately transferable immediately upon issuance. See "Plan of Distribution" and "Description of Securities". This offering is only being made to holders of the Company's outstanding Warrants. THESE SECURITIES ARE SPECULATIVE AND INVOLVE A HIGH DEGREE OF RISK AND SHOULD BE PURCHASED ONLY BY PERSONS WHO CAN AFFORD TO LOSE THEIR ENTIRE INVESTMENT. FOR A DESCRIPTION OF CERTAIN IMPORTANT FACTORS THAT SHOULD BE CONSIDERED BY PROSPECTIVE INVESTORS, SEE "RISK FACTORS" BEGINNING ON PAGE 9 OF THIS PROSPECTUS AND "DILUTION AND COMPARATIVE SHARE DATA". THESE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SECURITIES AND EXCHANGE COMMISSION NOR HAS THE COMMISSION PASSED UPON THE ACCURACY OR ADEQUACY OF THIS PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE. On November 14, 1997 the closing prices of the Company's Common Stock and Warrants on the American Stock Exchange were $8.50 and $0.62 respectively. As of the date of this Prospectus, there were 5,175,000 Warrants and 11,159,660 shares of Common Stock outstanding. The Company does not intend to pay any commissions or other forms of compensation to any person in connection with this offering. The expenses payable by the Company in connection with this offering are estimated to be $40,000. The exercise of any Warrants pursuant to the Exchange Offer will be revocable until the Expiration Date and, if not yet accepted by the Company, after March 7, 1998. The Company intends to accept the exercise of all Warrants timely submitted to the Company in proper form. Warrants that are not exercised pursuant to the Exchange Offer, or are exercised but timely withdrawn, may nevertheless be exercised at any time prior to February 7, 1998 (the "Warrant Expiration Date"). Any Warrants not exercised pursuant to the Exchange Offer will be of no value after the Warrant Expiration Date. See "Description of Securities". Any holder of the Warrants desiring to exercise all or any portion of the Warrants in accordance with the Exchange Offer should either (1) complete and sign the Letter of Transmittal (or facsimile thereof) in accordance with the instructions in the Letter of Transmittal and mail it or deliver it with the certificate(s) representing such Warrants together with the required cash payment to the Warrant Agent or (2) request his broker, dealer, commercial bank, trust company or other nominee to effect the transaction for such holder. A Warrant holder having Warrants registered in the name of a broker, dealer, commercial bank, trust company or other nominee must contact such person if the Warrant holder desires to exercise the Warrants. This offering is not contingent upon the exercise of any minimum number of Warrants. The date of this Prospectus is November 14, 1997 AVAILABLE INFORMATION The Company is subject to the informational requirements of the Securities Exchange Act of l934 and in accordance therewith is required to file reports, proxy statements and other information with the Securities and Exchange Commission (the "Commission"). Copies of any such reports, proxy statements and other information filed by the Company can be inspected and copied at the public reference facility maintained by the Commission at Room 1024, 450 Fifth Street, N.W., Washington, D.C. and at the Commission's Regional offices in New York (7 World Trade Center, Suite 1300, New York, New York 10048) and Chicago (Northwestern Atrium Center, 500 West Madison Street, Suite 1400, Chicago, Illinois 60661-2511). Copies of such material can be obtained from the Public Reference Section of the Commission at its office in -2- Washington, D.C. 20549 at prescribed rates. Certain information concerning the Company is also available at the Internet Web Site maintained by the Securities and Exchange Commission at www.sec.gov. The Company has filed with the Commission a Registration Statement on Form S-3 (together with all amendments and exhibits thereto, the "Registration Statement") under the Securities Act of 1933, as amended (the "Act"), with respect to the Securities offered hereby. This Prospectus does not contain all of the information set forth in the Registration Statement, certain parts of which are omitted in accordance with the rules and regulations of the Commission. For further information, reference is made to the Registration Statement. DOCUMENTS INCORPORATED BY REFERENCE The Company will provide, without charge, to each person to whom a copy of this Prospectus is delivered, including any beneficial owner, upon the written or oral request of such person, a copy of any or all of the documents incorporated by reference herein (other than exhibits to such documents, unless such exhibits are specifically incorporated by reference into this Prospectus). Requests should be directed to: CEL-SCI Corporation 66 Canal Center Plaza, Suite 510 Alexandria, VA 22314 (703) 549-5293 Attention: Secretary The following documents filed with the Commission by the Company (Commission File No. 0-11503) are hereby incorporated by reference into this Prospectus: (1) The Company's Annual Report on Form 10-K/A for the fiscal year ended September 30, 1996; and (2) The Company's report on Form 10-Q for the nine months ending June 30, 1997 (3) The Company's Proxy Statement relating to the Company's June 3, 1997 Annual Meeting of Shareholders. All documents filed with the Commission by the Company pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the date of this Prospectus and prior to the termination of the offering registered hereby shall be deemed to be incorporated by reference into this Prospectus and to be a part hereof from the date of the filing of such documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for the purposes of this Prospectus to the extent that a statement contained herein or in any subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Prospectus. -3- PROSPECTUS SUMMARY THIS SUMMARY SHOULD BE READ IN CONJUNCTION WITH, AND IS QUALIFIED IN ITS ENTIRETY BY, THE MORE DETAILED INFORMATION AND FINANCIAL STATEMENTS APPEARING ELSEWHERE IN THIS PROSPECTUS. The Company CEL-SCI Corporation (the "Company") was formed as a Colorado corporation in 1983. The Company is involved in the research and development of certain drugs and vaccines. The Company's first product, MULTIKINETM, manufactured using the Company's proprietary cell culture technologies, is a combination, or "cocktail", of natural human interleukin-2 ("IL-2") and certain lymphokines and cytokines. MULTIKINE is being tested to determine if it is effective in improving the immune response of cancer pantients. The Company's second product, HGP-30, is being tested to determine if it is an effective treatment/vaccine against the AIDS virus. In addition, the Company recently acquired a new patented T-cell Modulation Process which uses "heteroconjugates" to direct the body to chose a specific immune response. The Company intends to use this new technology to improve the cellular immune response of persons vaccinated with HGP-30 and to develop potential treatments and/or vaccines against various diseases. Present target diseases are herpes simplex, malaria, tuberculosis, prostate cancer and breast cancer. Before human testing can begin with respect to a drug or biological product, preclinical studies are conducted in laboratory animals to evaluate the potential efficacy and the safety of a product. Human clinical studies generally involve a three-phase process. The initial clinical evaluation, Phase I, consists of administering the product and testing for safe and tolerable dosage levels. Phase II trials continue the evaluation of immunogenicity and determine the appropriate dosage for the product, identify possible side effects and risks in a larger group of subjects, and provide preliminary indications of efficacy. Phase III trials consist of testing for actual clinical efficacy for safety within an expanded group of patients at geographically dispersed test sites. In March 1995, the Canadian Health Protection Branch, Health and Welfare Ministry gave clearance to the Company to start a Phase I/II cancer study using MULTIKINE. The study, which will enroll up to 30 head and neck cancer patients who have failed conventional treatments, will be conducted at several sites in the United States and Canada and is designed to evaluate safety, tumor responses and immune responses in patients treated with multiple courses of MULTIKINE. The length of time that each patient will remain on the investigational treatment will depend on the patient's response to treatment. In February 1996 the FDA authorized the Company to conduct two human clinical studies using MULTIKINE and focusing on prostate and head and neck cancer. The prostate study was conducted at Jefferson Hospital in Philadelphia, Pennsylvania and involved prostate cancer patients who had failed on hormonal therapy. Five patients completed the treatment and the data from this study demonstrated the safety and feasibility of using -4- MULTIKINE in the treatment of prostrate cancer. Biopsies from the patients in the study also suggest the recruitment of inflammatory cells to the tumor site. Based on these findings, investigators are currently preparing a new protocol for evaluation by the FDA to study the ability of MULTIKINE to treat patients with prostate cancer. The study is expected to test MULTIKINE as a therapy to be used prior to surgical removal of the prostate gland. The head and neck cancer study will involve up to 30 cancer patients who have failed using conventional therapies. The head and neck cancer study in the U.S. is being conducted in conjunction with the Company's Canadian head and neck cancer study. In January 1997 the FDA authorized a clinical trial using MULTIKINE to determine its safety in the potential treatment of HIV infected individuals and to determine its effect on various immune system responses. In April 1997, pursuant to authorization from Israeli health authorities, a clinical trial was begun using MULTIKINE to treat head and neck cancer patients. In September 1997 the Company started a similiar clinical trial in Canada. The Canadian study will involve up to 21 patients who are scheduled for surgery or radiation. The first clinical center to start treatment is Hospital Notre Dame in Montreal, Canada. Viral Technologies, Inc. ("VTI"), a wholly-owned subsidiary of the Company, is engaged in the development of a possible treatment/vaccine for AIDS. VTI's technology may also have application in the treatment of AIDS-infected individuals and the diagnosis of AIDS. VTI's AIDS treatment/vaccine, HGP-30, has completed certain Phase I human clinical trials. In the Phase I trials, the vaccine was administered to volunteers who were not infected with the HIV virus in an effort to determine safe and tolerable dosage levels. In April 1995 VTI, with the approval of the California Department of Health Services Food and Drug Branch (FDB), began another clinical trial in California using volunteers who received two vaccinations. The volunteers receiving the two lowest dosage levels were asked to donate blood for a SCID mouse HIV challenge study. The SCID mouse is considered to be the best available animal model for HIV because it lacks its own immune system and therefore permits human cell growth. White blood cells from the five (5) vaccinated volunteers and from normal donors were injected into groups of SCID mice. They were then challenged with high levels of a different strain of the HIV virus than the one from which HGP-30 is derived. Infection by virus was determined and confirmed by two different assays, p24 antigen, a component of the virus core, and reverse transcriptase activity, an enzyme critical to HIV replication. Approximately 78% of the SCID mice given blood from vaccinated volunteers showed no HIV infection after virus challenge as compared to 13% of the mice given blood from unvaccinated donors. In September 1997 VTI completed a Phase I safety study of the HGP-30 AIDS vaccine in 24 HIV infected patients. The study showed that immunizations with the HGP-30 vaccine coupled with KLH were safe in AIDS patients. The Company's main focus is now to determine the ability of the HGP-30 vaccine to prevent, as opposed to only treat, AIDS. -5- All of the Company's products are in the early stages of development. The Company does not expect to develop commercial products for several years, if at all. The Company has had operating losses since its inception, had an accumulated deficit of approximately $36,850,000 at June 30, 1997, and expects to incur substantial losses for the foreseeable future. In August 1996 the Company sold, in a private transaction, 5,000 shares of its Series B Preferred Stock (the "Series B Preferred Shares") for $5,000,000 or $1,000 per share. At the purchasers' option, up to 2,500 Series B Preferred Shares were convertible, on or after ten days from the date the shares were registered for public sale (the "Effective Date"), into shares of the Company's Common Stock on the basis of one share of Preferred Stock for shares of Common Stock equal in number to the amount determined by dividing $1,000 by 87% of the Closing Price of the Company's Common Stock. All Preferred Shares were convertible, on or after 40 days from the Effective Date, on the basis of one share of Preferred Stock for shares of the Company's Common Stock equal in number to the amount determined by dividing $1,000 by 85% of the Closing Price of the Company's Common Stock. The term "Closing Price" was defined as the average closing bid price of the Company's Common Stock over the five-day trading period ending on the day prior to the conversion of the Preferred Stock. Notwithstanding the above, the conversion price could not be less than $3.60 nor more than $14.75. Each Preferred Share was entitled to a quarterly dividend, if, as, and when declared by the Board of Directors, of $17.50. By means of a separate Registration Statement filed with the Securities and Exchange Commission, the shares issuable upon the conversion of the Series B Preferred Shares were registered for public sale. Prior to December 20, 1996 1,900 Series B Preferred Shares were converted into 527,774 shares of the Company's common stock. In December 1996 the Company repurchased 2,850 Series B Preferred Shares for $2,850,000 plus warrants which allow the holders to purchase up to 99,750 shares of the Company's common stock for $4.25 per share at any time prior to December 15, 1999. The Company raised funds required for this repurchase from the sale of its Series C Preferred Stock. In May 1997 all remaining 250 shares of the Series B Preferred Stock were converted into 69,444 shares of common stock. In December 1996 the Company raised $2,850,000 from the sale of units consisting of 2,850 shares of the Company's Series C Preferred Stock, 379,763 Series A Warrants and 379,763 Series B Warrants. The Series C Preferred Shares were convertible into shares of the Company's Common Stock on the basis of one share of Preferred Stock for shares of Common Stock equal in number to the amount determined by dividing $1,000 by 85% of the Closing Price of the Company's Common Stock (the "Conversion Price"). The term "Closing Price" was defined as the average closing bid price of the Company's Common Stock over the five day trading period ending on the day prior to the conversion of the Preferred Stock. Notwithstanding the above, the Conversion Price could not be more than $4.00. Each Series A Warrant entitles the holder to purchase one share of the Company's common stock at a price of $4.50 per share at any time prior to March 15, 1998. Each Series B Warrant entitles the holder to purchase one share of the Company's common stock at a price of $4.50 per share at any time prior to March 15, 1999. The shares issuable upon the conversion of the Series C Preferred Shares and the exercise of the Warrants are being offered for public sale by means of a separate Registration Statement. As of June 30, 1997 all shares of the Series C Preferred Stock had been converted into 9l5,27l shares of the Company's common stock. -6- Acquisition of MULTIKINE Technology The MULTIKINE technology being tested by the Company was developed by a group of researchers and was assigned, during l980 and l98l, to Hooper Trading Company, N.V., a Netherlands Antilles' corporation ("Hooper"), and Shanksville Corporation, also a Netherlands Antilles corporation ("Shanksville"). The MULTIKINE technology assigned to Hooper and Shanksville was licensed to Sittona Company, B.V., a Netherlands corporation ("Sittona"), effective September, l982 pursuant to a licensing agreement which required Sittona to pay Hooper and Shanksville royalties on income received by Sittona with respect to the MULTIKINE technology. In l983, Sittona licensed the MULTIKINE Technology to the Company and received from the Company a $1,400,000 advance royalty payment. At such time as the Company generated revenues from the sale or sublicense of this technology, the Company was required to pay royalties to Sittona equal to l0% of net sales and l5% of the licensing royalties received from third parties. In that event, Sittona, pursuant to its licensing agreements with Hooper and Shanksville, was required to pay to those companies a minimum of l0% of any royalty payments received from the Company. The license agreement with Sittona also required the Company to bear the expense of preparing, filing and processing patent applications and to obtain and maintain patents in the United States and foreign countries on all inventions, developments and improvements made by or on behalf of the Company relating to the MULTIKINE technology. The license was to remain in effect until the expiration or abandonment of all patent rights or until the MULTIKINE technology entered into the public domain, whichever was later. Prior to October, 1996, Maximilian de Clara, an Officer, Director and shareholder of the Company, owned 50% and 30%, respectively, of Hooper and Shanksville. Between 1985 and October 1996 Mr. de Clara owned all of the issued and outstanding stock of Sittona. In October 1996, Mr. de Clara disposed of his interest in Hooper, Shanksville and Sittona. In January 1997 Hooper and Shanksville sold all of their rights in the MULTIKINE technology to Sittona. Immediately following these transactions, Sittona sold all of its rights in the MULTIKINE technology to the Company, including all rights acquired from Hooper and Shanksville, in consideration for $500,000 in cash and 751,678 shares of the Company's common stock. The shares of the Company's Common Stock acquired by Sittona as a result of this transaction are being offered to the public by means of a separate Registration Statement. The Company's executive offices are located at 66 Canal Center Plaza, Suite 510, Alexandria, Virginia 22314, and its telephone number is (703) 549-5293. The Offering This Prospectus relates to the sale by the Company of 1,035,000 shares of common stock which are issuable upon the exercise of 5,175,000 Warrants which were issued in connection with the Company's February 1992 public offering of Units. Each Unit sold in such offering consisted of five shares of Common Stock and five Common Stock Purchase Warrants (the "Warrants"). -7- The Warrants are exercisable at any time prior to February 7, 1998 (the "Warrant Expiration Date"). The terms of the Warrants presently provide that every five Warrants allow the holder to purchase one share of the Company's Common Stock at a price of $6.00 per share. The Company, upon certain conditions, may accelerate the expiration date of the Warrants. Notwithstanding the above, at any time between January 9, 1998 and February 6, 1998 every five Warrants will allow the holder to purchase, for $6.00, one share of the Company's common stock and one Series A Warrant. Each Series A Warrant entitles the holder to purchase one share of the Company's Common Stock at a price of $18.00 per share at any time prior to February 7, 2000. The foregoing offer (the "Exchange Offer"), unless extended by the Company, will expire on February 6, l998 (the "Expiration Date"). The expiration date of the Series A Warrants may be accelerated under certain conditions. The shares of Common Stock and Series A Warrants will be separately transferable immediately upon issuance. See "Plan of Distribution" and "Description of Securities". Use of proceeds. The proceeds from this offering will be used to finance the Company's business, including research, clinical trials and general and administrative expenses. See "Use of Proceeds". Shares Outstanding. As of October 31, 1997 the Company had 11,159,660 issued and outstanding shares of Common Stock. The number of shares outstanding excludes shares of Common Stock issuable upon the exercise of currently outstanding options and warrants, and shares of Common Stock issuable upon the conversion of other convertible securities issued by the Company. See "Dilution and Comparative Share Data." Risk Factors The purchase of the Securities offered by this Prospectus involves a high degree of risk. Risk factors include the following: lack of revenues and history of loss, need for additional capital, government regulation, need for FDA approval, and dilution. See "Risk Factors." AMEX Symbols: Common Stock: HIV Warrants: HIV WS Series A Warrants: HIV WA (1) (1) The Company will make an application to have the Series A Warrants listed on the American Stock Exchange. No assuarance can be given that the American Stock Exchange will approve the listing of the Series A Warrants. See "Risk Factors." Summary Financial Data Nine Months Ended Years Ended September 30, June 30, 1997 1996 1996 1995 Investment Income & Other Revenues $378,264 $188,256 $322,370 $423,765 Expenses: Research and Development 4,795,504 2,350,600 3,471,477 1,824,661 -8- Summary Financial Data Nine Months Ended Years Ended September 30, June 30, 1997 1996 1996 1995 Depreciation and Amortization 236,541 208,912 290,829 262,705 General and Administrative 1,799,454 2,113,884 2,882,958 1,713,912 Equity in loss of joint venture - 3,772 3,772 501,125 Net Loss $(6,453,235) (4,488,912) $(6,326,666) $(3,878,638) Loss per common share $(0.72) $(0.74) $(0.98) $(0.89) Weighted average common shares outstanding 8,970,583 6,086,492 6,425,316 4,342,628 Balance Sheet Data June 30, September 30, 1997 1996 1996 1995 Total Assets $7,663,646 $8,723,934 $11,878,370 $6,359,011 Working Capital 6,028,270 6,979,975 10,266,104 3,983,699 Current Liabilities 306,752 355,684 274,410 491,860 Long Term and Other Liabilities 19,638 835,316 19,638 1,025,118 Total Liabilities 326,390 1,191,000 294,048 1,516,978 Shareholders' Equity 7,337,256 7,532,934 11,584,322 4,842,033 Book Value per Share $0.70 $1.06 $1.47 $0.90 No common stock dividends have been declared by the Company since its inception. RISK FACTORS An investment in the Company's Securities involves a high degree of risk. Prospective investors are advised that they may lose all or part of their investment. Prospective investors should carefully review the following risk factors. -9- Lack of Revenues and History of Loss. The Company has had only limited revenues since it was formed in 1983. Since the date of its formation and through June 30, 1997, the Company has incurred net losses of approximately $36,850,000. During the years ended September 30, 1994, 1995 and 1996 the Company suffered losses of $4,426,876, $3,878,638 and $6,326,666 respectively. The Company has relied principally upon the proceeds from the public and private sales of securities to finance its activities to date. All of the Company's potential products are in the early stages of development, and any commercial sale of these products will be many years away. Accordingly, the Company expects to incur substantial losses for the foreseeable future. Need for Additional Capital. Clinical and other studies necessary to obtain approval of a new drug can be time-consuming and costly, especially in the United States, but also in foreign countries. The different steps necessary to obtain regulatory approval, especially that of the Food and Drug Administration ("FDA"), involve significant costs. The Company expects that it will need additional financing in order to fund the costs of future clinical trials, related research, and general and administrative expenses. The Company may be forced to delay or postpone development and research expenditures if the Company is unable to secure adequate sources of funds. These delays in development may have an adverse effect on the Company's ability to produce a timely and competitive product. There can be no assurance that the Company will be able to obtain additional funding from other sources. Viral Technologies, Inc. ("VTI"), a wholly-owned subsididary of the Company, is dependent upon funding from the Company for its operations and research programs. Cost Estimates. The Company's estimates of the costs associated with future clinical trials and research may be substantially lower than the actual costs of these activities. If the Company's cost estimates are incorrect, the Company will need additional funding for its research efforts. Government Regulation - FDA Approval. Products which may be developed by the Company or Viral Technologies, Inc. (or which may be developed by affiliates or licensees) will require regulatory approvals prior to sale. In particular, therapeutic agents and diagnostic products are subject to approval, prior to general marketing, by the FDA in the United States and by comparable agencies in most foreign countries. The process of obtaining FDA and corresponding foreign approvals is costly and time consuming, particularly for pharmaceutical products such as those which might ultimately be developed by the Company, VTI or its licensees, and there can be no assurance that such approvals will be granted. Any failure to obtain or any delay in obtaining such approvals may adversely affect the ability of potential licensees or the Company to successfully market any products developed. Also, the extent of adverse government regulations which might arise from future legislative or administrative action cannot be predicted. The clinical trial which VTI is conducting in California is regulated by government agencies in California and obtaining approvals from states for clinical trials is likewise expensive and time consuming. -10- Dependence on Others to Manufacture Product. The Company has an agreement with an unrelated corporation for the production, until 1998, of MULTIKINE for research and testing purposes. At present, this is the Company's only source of MULTIKINE. If this corporation could not, for any reason, supply the Company with MULTIKINE, the Company estimates that it would take approximately six to ten months to obtain supplies of MULTIKINE under an alternative manufacturing arrangement. The Company does not know what cost it would incur to obtain this alternative source of supply. Technological Change. The biomedical field in which the Company is involved is undergoing rapid and significant technological change. The successful development of vaccines, therapeutic agents and diagnostic products from the Company's compounds, compositions and processes through Company financed research or as a result of possible licensing arrangements with pharmaceutical or other companies, will depend on its ability to be in the technological forefront of this field. There can be no assurance that the Company will achieve or maintain such a competitive position or that other technological developments will not cause the Company's proprietary technologies to become uneconomical or obsolete. Patents. Certain aspects of the Company's technologies are covered by U.S. and foreign patents. In addition, the Company has a number of patent applications pending. There is no assurance that patent applications filed by the Company or which may be filed in the future will result in the issuance of any patents. Furthermore, there is no assurance as to the breadth and degree of protection any issued patents might afford the owners of the patents and the Company. Disputes may arise between the Company and others as to the scope, validity and ownership rights of these or other patents. Any defense of the patents could prove costly and time consuming and there can be no assurance that the Company will be in a position, or will deem it advisable, to carry on such a defense. Other private and public concerns, including universities, may have filed applications for, or may have been issued, patents and are expected to obtain additional patents and other proprietary rights to technology potentially useful or necessary to the Company. The scope and validity of such patents, if any, the extent to which the Company or the owners of the patents may wish or need to acquire the rights to such patents, and the cost and availability of such rights are presently unknown. Also, as far as the Company relies upon unpatented proprietary technology, there is no assurance that others may not acquire or independently develop the same or similar technology. The Company's first MULTIKINE patent will expire in the year 2000. Since the Company does not know if it will ever be able to sell MULTIKINE on a commercial basis, the Company cannot predict what effect the expiration of this patent will have on the Company. Notwithstanding the above, the Company believes that later issued patents will protect the technology associated with MULTIKINE past the year 2000. Product Liability. Although the Company has product liability insurance for MULTIKINE and its HGP-30 vaccine, the successful prosecution of a product liability case against the Company could have a materially adverse effect upon its business if the amount of any judgment exceeds the Company's insurance coverage. -11- Dependence on Management and Scientific Personnel. The Company is dependent for its success on the continued availability of its executive officers. The loss of the services of any of the Company's executive officers could have an adverse effect on the Company's business. The Company does not carry key man life insurance on any of its officers. The Company's future success will also depend upon its ability to attract and retain qualified scientific personnel. There can be no assurance that the Company will be able to hire and retain such necessary personnel. Options, Warrants and Convertible Securities. The Company has issued options, warrants and other convertible securities ("Derivative Securities") which allow the holders to acquire additional shares of the Company's Common Stock. In some cases the Company has agreed that, at its expense, it will make appropriate filings with the Securities and Exchange Commission so that the securities underlying certain Derivative Securities will be available for public sale. Such filings could result in substantial expense to the Company and could hinder future financings by the Company. For the terms of these Derivative Securities, the holders thereof will have an opportunity to profit from any increase in the market price of the Company's Common Stock without assuming the risks of ownership. Holders of such Derivative Securities may exercise and/or convert them at a time when the Company could obtain additional capital on terms more favorable than those provided by the Derivative Securities. The exercise or conversion of the Derivative Securities will dilute the voting interest of the owners of presently outstanding shares of the Company's Common Stock and may adversely affect the ability of the Company to obtain additional capital in the future. The sale of the shares of Common Stock issuable upon the exercise or conversion of the Derivative Securities could adversely affect the market price of the Company's stock. See "Dilution and Comparative Share Data". Competition. The competition in the research, development and commercialization of products which may be used in the prevention or treatment of cancer and AIDS is intense. Major pharmaceutical and chemical companies, as well as specialized genetic engineering firms, are developing products for these diseases. Many of these companies have substantial financial, research and development, and marketing resources and are capable of providing significant long-term competition either by establishing in-house research groups or by forming collaborative ventures with other entities. In addition, both smaller companies and non-profit institutions are active in research relating to cancer and AIDS and are expected to become more active in the future. Determination of Offering Price. The exercise price of the Warrants (and the terms of the Exchange Offer) were determined by the Company based upon factors such as the Company's capital needs, the percentage of ownership to be held by Warrant holders, the general condition of the securities markets and other relevant factors. Neither the exercise price of the Warrants nor the terms of the Exchange Offer necessarily bear any relationship to the Company's assets, book value, earnings history or other investment criteria. -12- Offering Proceeds. There is no minimum number of Warrants which are required to be exercised in connection with in this Offering. Accordingly, if only a limited number of Warrants are exercised, the corresponding proceeds to the Company from this Offering may be small. See "Use of Proceeds". Warrants. In connection with the Exchange Offer, the Company has applied to have the Series A Warrants listed for trading on the American Stock Exchange. In order for the Series A Warrants to be listed on the American Stock Exchange, there must be at least 100,000 Series A Warrants issued and outstanding. Since there is no minimum number of Warrants which are required to be exercised in the Exchange Offer, no assurance can be given that the number of Series A Warrants which will be issued and outstanding following the expiration of the Exchange Offer will be sufficient so as to allow the listing of the Series A Warrants on the American Stock Exchange. If the Series A Warrants cannot be listed on the American Stock Exchange, the Company will attempt to have the Warrants listed for trading on the NASD's Electronic Bulletin Board. Lack of Dividends. There can be no assurance the Company will be profitable. At the present time, the Company intends to use available funds to finance the Company's operations. Accordingly, while payment of dividends rests within the discretion of the Board of Directors, no common stock dividends have been declared or paid by the Company. The Company does not presently intend to pay dividends on its common stock and there can be no assurance that common stock dividends will ever be paid. Dilution. Persons purchasing the securities offered by this Prospectus will suffer immediate dilution since the price paid for the securities offered will likely be more than the net tangible book value of the Company's Common Stock. See "Dilution and Comparative Share Data." Preferred Stock. The Company's Articles of Incorporation authorize the Company's Board of Directors to issue up to 200,000 shares of Preferred Stock. The provisions in the Company's Articles of Incorporation relating to the Preferred Stock allow the Company's directors to issue Preferred Stock with multiple votes per share and dividends rights which would have priority over any dividends paid with respect to the Company's Common Stock. The issuance of Preferred Stock with such rights may make the removal of management difficult even if such removal would be considered beneficial to shareholders generally, and will have the effect of limiting shareholder participation in certain transactions such as mergers or tender offers if such transactions are not favored by incumbent management. USE OF PROCEEDS The net proceeds to the Company from this (assuming all Warrants are exercised) are estimated to be approximately $6,200,000. The Company anticipates that the net proceeds from this offering will be used to finance the Company's research, clinical trials and general and administrative expenses. -13- Notwithstanding the above, there is no minimum number of Warrants which is required to be sold in this Offering. Accordingly, if only a limited number of Warrants are exercised, the corresponding proceeds to the Company from this Offering will be minimal. DILUTION AND COMPARATIVE SHARE DATA As of October 31, 1997 the Company had 11,159,660 shares of Common Stock issued and outstanding with a net tangible book value (total assets less total liabilities and intangible assets) of $0.67 per share. The following illustrates per share dilution to investors in this offering as well as other comparative share data, assuming all Warrants are exercised. The number of shares outstanding excludes shares of Common Stock issuable on exercise of outstanding options, warrants and other convertible securities previously issued by the Company or which may be issued by the Company in connection with this offering. Public Offering Price (Price of One Share of Common Stock Upon Exercise of Warrants) ................ $6.00 Shares Outstanding As Of October 31, 1997 ............................. 11,159,660 Shares to be issued in this Offering (1) ......................... 1,035,000 Shares Outstanding After This Offering (3) ......................... 12,194,660 Net Tangible Book Value Per Share of Common Stock Prior To This Offering ................ ............ $0.67 Pro Forma Net Tangible Book Value Per Share of Common Stock After This Offering ........................ $1.15 Gain in Book Value Per Share to Present Shareholders ................. $0.48 Dilution Per Share to Purchasers of Common Stock ...................... $4.85 Equity Ownership by Present Shareholders Following Offering ..... 91% Equity Ownership by Investors in this Offering ........................ 9% "Net tangible book value" is the amount that results from subtracting the total liabilities and intangible assets of the Company from its total assets. Tangible assets exclude deposits and patent costs. "Dilution" is the difference between the public offering price and the net tangible book value of the Company's shares of Common Stock immediately after the Offering. (1) Assumes all Warrants are exercised, of which there can be no assurance. In the case of the Exchange Offer, does not reflect shares of common stock issuable upon the exercise of the Series A Warrants. (2) Every five Warrants will allow the holder to purchase, for $6.00, one share of the Company's Common Stock and one Series A Warrant. See "Plan of Distribution". -14- (3) Does not reflect shares of common stock issuable upon the exercise of the Series A Warrants or additional shares which may be issued as the result of the exercise of outstanding options and warrants or the conversion of other securities issued by the Company, as shown by the following: Number of Note Shares Reference Outstanding as of October 31, 1997 11,159,660 Shares offered by this Prospectus 1,035,000 Other Shares Which May Be Issued: Shares issuable upon exercise of Series A Warrants 1,035,000 A Shares issuable upon exercise of Class A and Class B Warrants 233,188 B Shares issuable upon exercise of warrants held by former holders of the Company's Series B Preferred Stock. 82,250 C Shares issuable upon exercise of options granted to Company's officers, directors, employees and consultants 2,481,654 D Shares outstanding (as adjusted), assuming all Warrants are exercised: 16,026,752 A. Pursuant to the terms of the Exchange Offer, at any time between January 9, 1998 and February 6, 1998 every five Warrants will allow the holder to purchase, for $6.00, one share of the Company's common stock and one Series A Warrant. Each Series A Warrant entitles the holder to purchase one share of the Company's Common Stock at a price of $18.00 per share at any time prior to February 7, 2000. The Exchange Offer, unless extended by the Company, will expire on February 6, 1998 (the "Expiration Date"). See "Description of Securities". B. In December 1996 the Company raised $2,850,000 from the sale of units consisting of 2,850 shares of the Company's Series C Preferred Stock, 379,763 Class A Warrants and 379,763 Class B Warrants. The Series C Preferred Shares were convertible into shares of the Company's Common Stock on the basis of one share of Preferred Stock for shares of Common Stock equal in number to the amount determined by dividing $1,000 by the 85% of Closing Price of the Company's Common Stock (the "Conversion Price"). The term "Closing Price" was defined as the average closing bid price of the Company's Common Stock over the five-day trading period ending on the day prior to the conversion of the Preferred Stock. Notwithstanding the above, the Conversion Price could not be more than $4.00. Each Class A Warrant entitles the holder to purchase one share of -15- the Company's common stock at a price of $4.50 per share at any time prior to March 15, 1998. Each Class B Warrant entitles the holder to purchase one share of the Company's common stock at a price of $4.50 per share at any time prior to March 15, 1999. By means of a separate Registration Statement, the shares issuable upon the conversion of the Series C Preferred Shares and the exercise of the Class A Warrants and Class B Warrants are being offered for public sale. As of October 31, 1997 all shares of the Series C Preferred Stock had been converted into 9l5,27l shares of the Company's common stock, 273,163 Class A Warrants had been exercised and 253,175 Class B Warrants had been exercised. C. In August 1996 the Company sold, in a private transaction, 5,000 shares of its Series B Preferred Stock (the "Preferred Shares") for $5,000,000 or $1,000 per share. At the purchasers' option, up to 2,500 Preferred Shares were convertible, on or after November 7, 1996 (the "Effective Date"), into shares of the Company's Common Stock on the basis of one share of Preferred Stock for shares of Common Stock equal in number to the amount determined by dividing $1,000 by 87% of the Closing Price of the Company's Common Stock. All Preferred Shares were convertible, on or after 40 days from the Effective Date, on the basis of one share of Preferred Stock for shares of the Company's Common Stock equal in number of the amount determined by dividing $1,000 by 85% of the Closing Price of the Company's Common Stock. The term "Closing Price" was defined as the average closing bid price of the Company's Common Stock over the five-day trading period ending on the day prior to the conversion of the Preferred Stock. Notwithstanding the above, the conversion price could not be less than $3.60 nor more than $14.75. The Preferred Shares were entitled to a quarterly dividend of $17.50 per share. By means of a separate Registration Statement filed with the Securities and Exchange Commission, the shares issued upon the conversion of the Series B Preferred Shares were registered for public sale. Prior to December 20, 1996 1,900 Series B Preferred Shares were converted into 527,774 shares of the Company's common stock. In December 1996 the Company repurchased 2,850 Series B Preferred Shares for $2,850,000 plus warrants which allow the holders to purchase up to 99,750 shares of the Company's common stock for $4.25 per share at any time prior to December 15, 1999. The Company raised the funds required for this repurchase from the sale of its Series C Preferred Stock. In May 1997 all remaining 250 shares of the Series B Preferred Stock were converted into 69,444 shares of common stock. As of October 31, l997 warrants for the purchase of 17,500 shares of common stock had been exercised. D. The options are exercisable at prices ranging from $2.38 to $19.70 per share. The Company may also grant options to purchase additional shares of Common Stock under its Incentive Stock Option and Non-Qualified Stock Option Plans. MARKET FOR THE COMPANY"S COMMON STOCK As of October 31, 1997, there were approximately 2,800 record holders of the Company's Common Stock and approximately 100 record holders of the Company's Warrants. Prior to June 5, 1997, the Company's Common Stock and Warrants were traded on the National Association of Securities Dealers -16- Automatic Quotation ("NASDAQ") System. Since June 5, 1997 the Company's Common Stock and Warrants have traded on the American Stock Exchange. Set forth below are the range of high and low quotations for the periods indicated as reported by NASDAQ and the American Stock Exchange, and as adjusted for the 10 for 1 reverse stock split which was approved by the Company's shareholders on April 28, 1995 and became effective on May 1, 1995. The market quotations reflect inter-dealer prices, without retail mark-up, mark-down or commissions and may not necessarily represent actual transactions. Quarter Ending Common Stock Warrants High Low High Low 12/31/94 $ 7.50 $ 3.40 $0.25 $0.09 3/31/95 $ 4.00 $ 3.75 $0.22 $0.13 6/30/95 $ 5.30 $ 2.78 $0.15 $0.06 9/30/95 $ 5.46 $ 3.56 $0.28 $0.09 12/31/95 $ 4.75 $ 2.28 $0.25 $0.09 3/31/96 $ 7.12 $ 2.68 $0.28 $0.03 6/30/96 $14.38 $ 4.56 $0.41 $0.16 9/30/96 $12.00 $ 5.62 $0.44 $0.21 12/31/96 $ 6.63 $ 3.50 $0.28 $0.12 3/31/97 $ 6.12 $ 4.19 $0.22 $0.12 6/30/97 $ 5.12 $ 2.75 $0.44 $0.09 9/30/97 $ 8.06 $ 3.12 $0.69 $0.19 Holders of Common Stock are entitled to receive such dividends as may be declared by the Board of Directors out of funds legally available therefor and, in the event of liquidation, to share pro rata in any distribution of the Company's assets after payment of liabilities. The Board of Directors is not obligated to declare a dividend. The Company has not paid any dividends on it's Common Stock and the Company does not have any current plans to pay any Common Stock dividends. The provisions in the Company's Articles of Incorporation relating to the Company's Preferred Stock would allow the Company's directors to issue Preferred Stock with rights to multiple votes per share and dividends rights which would have priority over any dividends paid with respect to the Company's Common Stock. The issuance of Preferred Stock with such rights may make more difficult the removal of management even if such removal would be considered beneficial to shareholders generally, and will have the effect of limiting shareholder participation in certain transactions such as mergers or tender offers if such transactions are not favored by incumbent management. PLAN OF DISTRIBUTION Regular Warrant Exercise The Warrants are exercisable at any time prior to February 7, 1998 (the "Warrant Expiration Date"). The terms of the Warrants presently provide that every five Warrants allows the holder to purchase one share of the Company's Common Stock at a price of $6.00 per share. The Company, upon 30-days notice, may accelerate the expiration date of the Warrants. -17- The Warrants may be exercised by sending properly completed and signed certificates to the Warrant Agent accompanied by payment in full of the exercise price for each share of Common Stock as to which the Warrants are being exercised. Payment for the exercise price of Warrants may be made by cash, wire transfer, bank cashier's check or personal check. Payments should be made to "American Securities Transfer". If payment is made by personal check the shares of common stock issuable upon the exercise of the Warrants will not be issued until the check has been paid by the Warrant holder's bank. Exchange Offer The terms of the Exchange Offer provide that at any time between January 9, 1998 and February 6, 1998 every five Warrants will allow the holder to purchase, for $6.00, one share of the Company's common stock and one Series A Warrant. Each Series A Warrant entitles the holder to purchase one share of the Company's Common Stock at a price of $18.00 per share at any time prior to February 7, 2000. The foregoing offer (the "Exchange Offer"), unless extended by the Company, will expire on February 6, 1998 (the "Expiration Date"). See "Description of Securities" for further information concerning the terms of the Series A Warrant. The purpose of the Exchange Offer is to provide an incentive for the exercise of the Company's outstanding Warrants. To the extent that Warrants are exercised pursuant to this Exchange Offer, the Company will benefit from the receipt of the cash received in conjunction with the exercise. Any Warrants accepted for exercise will be retired. The Board of Directors of the Company believes the Exchange Offer is in the best interests of the Company and that the Company will benefit from the receipt of cash proceeds, if any, received pursuant to the Exchange Offer. However, the Board of Directors is not making any recommendations to the holders of the Warrants as to whether they should excercise or refrain from exercising any or all of their Warrants. Each Warrant holder must make his or her own decision as to whether to exchange all or any portion of the Warrants owned by such person. Subject to the terms and conditions as set forth herein, the Company will accept all Warrants which are timely and properly tendered to American Securities Transfer, Inc., (the "Warrant Agent") under the terms of this Exchange Offer prior to 6:00 p.m. Denver, Colorado Time on February 6, 1998 (the "Expiration Date"). The Company at its sole option may extend the Exchange Offer for an additional period of time by giving written or oral notification of such extension to the Exchange Agent and by causing notice of any extension of the Exchange Offer to be mailed to all Warrant holders of record, and to be published in The New York Times, the Wall Street Journal or any other newspaper of national circulation selected by the Company. The Company has no present intention to extend the Exchange Offer beyond the Expiration Date. The Company reserves the right to withdraw, cancel, modify or terminate this Exchange Offer at any time prior to the Expiration Date (by written or oral notice to the Warrant Agent and by causing notice thereof to be given to all Warrant Holders of record) if, in the opinion of counsel for -18- the Company, there exists any actual or threatened legal impediment to the Exchange Offer, including any material legal action or administrative proceeding instituted or threatened against the Company or the Warrant Agent with respect to the Exchange Offer. No such impediments are presently known by the Company to exist. Upon any such termination of the Exchange Offer, the Company will return all such Warrants and cash payments without interest thereon or deduction therefrom, and have no further obligation or liability with respect to the Exchange Offer. Should any funds of any tendering Warrant holder whose exercise has not been accepted by the Company be left on deposit with the Warrant Agent for any reason including, but not limited to, termination of the Exchange Offer, the Warrant Agent will promptly refund such funds without interest thereon or deduction therefrom. No variation in the terms of the Exchange Offer is presently contemplated. However, if for any reason the terms should be changed, the revised terms will apply for all tendering Warrant holders whether they tendered before or after such change. Requests for additional copies of this Prospectus or the Letter of Transmittal or assistance in completing an exchange should be made by mail or telephone to any of the following: WARRANT AGENT: American Securities Transfer & Trust, Inc. 938 Quail St., Suite l0l Lakewood, Colorado 802l5 Telephone: (303) 534-5300 Attention: Administrative Services THE COMPANY: CEL-SCI Corporation 66 Canal Center Plaza Suite 510 Alexandria, Virginia 22314 Telephone: (703) 549-5293 Attention: Patricia B. Prichep Vice President of Operations The Warrant certificates and payments should NOT be sent to the Company. Warrant certificates and payments should be sent to the Warrant Agent. Payment should be made to "American Securities Transfer & Trust". If a holder of Warrants does not tender Warrants pursuant to the terms of this Exchange Offer, such holder may nevertheless exercise the Warrants in accordance with the terms of the Warrants. Such terms provide that every five Warrants entitle the holder to purchase one (1) share of the Company' Common Stock at a price of $6.00 at any time prior to February 7, 1998 (the "Warrant Expiration Date"). -19- Procedure for Exchange Offer Except as otherwise stated below, to be properly tendered pursuant to this Exchange Offer, a Warrant holder must send the Warrant Certificates, together with a properly completed and executed Letter of Transmittal and the applicable payment to the Warrant Agent prior to the Expiration Date. The certificates, Letter of Transmittal and the payment should not be sent to the Company. The method of delivery of the Warrants, the payment and other documents forwarded to the Warrant Agent is at the election and risk of the holder, but if such delivery is by mail it is suggested that registered mail with return receipt requested be used. The applicable payment accompanying the Warrants must be made by cash, wire transfer, bank cashier's check or personal check payable in United States dollars to American Securities Transfer & Trust, Inc. as Warrant Agent. If payment is made by personal check, the shares of common stock and Series A Warrants will not be issued until the check has been paid by the Warrant holder's bank. All questions as to the validity, form, eligibility (including time of receipt) and acceptance of the Warrants or payments tendered will be determined by the Company, which determination shall be final and binding. The Company reserves the absolute right to reject any or all tenders of any Warrants and payments not properly tendered or any acceptence of which would, in the opinion of the Company, be unlawful. The Company also reserves the right to waive any irregularities or conditions of tender as to any particular Warrants, and the Company's interpretation of the terms and conditions of the Exchange Offer (including the instrutions and Letter of Transmittal) shall be final and binding. Any irregularities in connection with the tenders, unless waived, must be cured within such time as the Company shall determine, which time may be extended beyond the Expiration Date. Neither the Company nor the Warrant Agent shall be under any duty to give notification of defects in such tenders or incur any liability for failure to give such notification. Tenders of the Warrants and payments received by the Warrant Agent that are not properly tendered and as to which the irregularities have not been cured or waived will be returned (without interest on the payment or deduction therefrom) by the Warrant Agent to the appropriate Warrant holder as soon as practicable. Procedure for Late Delivery of Warrants If the Warrant Agent receives, prior to the Expiration Date, the applicable payment with respect to the number of Warrants being exercised, together with a letter or facsimile transmission from a commercial bank or trust company in the United States, a member of the National Association of Securities Dealers, Inc. or a member firm of a national securities exchange stating the number of Warrants being excercised, the name of the holder of the Warrants and guaranteeing that the Warrants and/or Letter of Transmittal, as the case may be, and any other documents required for such exercise will be received by the Warrant Agent within three (3) business days of the Expiration Date, such tender will be accepted subject to the receipt by the Warrant Agent of the guaranteed items within the specified period. The guarantee of delivery of Warrants may also be effected by executing and delivering to the Warrant Agent prior to the Expiration Date, the applicable payment and a Letter of Transmittal with the guarantee of delivery contained therein separately executed by one of the aforementioned institutions. -20- Withdrawal Rights Tenders of Warrants and payments may be withdrawn at any time prior to the termination of the Exchange Offer and, if not yet accepted for excercise, after March 7, 1998. For a withdrawal to be effective, a written or facsimile transmission notice of withdrawal must be timely received by the Warrant Agent at its address as set forth above. Such notice of withdrawal must set forth the name of the tendering Warrant holder, the name of the registered holder if different from that of the Warrant holder, the number of Warrants (and, if available, the certificate numbers) and the amount of the payment to be withdrawn. All questions as to the validity (including time of receipt) or notices of withdrawal will be determined by the Company, whose determination shall be final and binding. All Warrants and payments withdrawn in the manner specified above will not be considered to have been duly exercised. Delivery of Common Stock and Series A Warrants Upon the terms and subject to the conditions of this Exchange Offer, delivery of the Common Stock and Series A Warrants in exchange for the Warrants and cash payments validly tendered and accepted by the Company will be made as soon as practicable after the Expiration Date. It is anticipated that the certificates for the Shares of Common Stock and Series A Warrants will be mailed within three business days of the Expiration Date. All deliveries will be made through the Warrant Agent. DESCRIPTION OF SECURITIES Common Stock The Company is authorized to issue 100,000,000 shares of Common Stock, (the "Common Stock"). Holders of Common Stock are each entitled to cast one vote for each share held of record on all matters presented to shareholders. Cumulative voting is not allowed; hence, the holders of a majority of the outstanding Common Stock can elect all directors. Holders of Common Stock are entitled to receive such dividends as may be declared by the Board of Directors out of funds legally available therefor and, in the event of liquidation, to share pro rata in any distribution of the Company's assets after payment of liabilities. The board is not obligated to declare a dividend. It is not anticipated that dividends will be paid in the foreseeable future. Holders of Common Stock do not have preemptive rights to subscribe to additional shares if issued by the Company. There are no conversion, redemption, sinking fund or similar provisions regarding the Common Stock. All of the outstanding shares of Common Stock are fully paid and nonassessable and all of the shares of Common Stock issuable upon the exercise of the Series A Warrants will be, upon issuance, fully paid and non-assessable. -21- Preferred Stock The Company is authorized to issue up to 200,000 shares of Preferred Stock. The Company's Articles of Incorporation provide that the Board of Directors has the authority to divide the Preferred Stock into series and, within the limitations provided by Colorado statute, to fix by resolution the voting power, designations, preferences, and relative participation, special rights, and the qualifications, limitations or restrictions of the shares of any series so established. As the Board of Directors has authority to establish the terms of, and to issue, the Preferred Stock without shareholder approval, the Preferred Stock could be issued to defend against any attempted takeover of the Company. In May 1996 the Company sold 3,500 shares of its Series A Preferred Stock (the "Preferred Shares") for $3,500,000 or $1,000 per share. All Preferred Shares were convertible on the basis of one share of Preferred Stock for shares of the Company's Common Stock equal in number to the amount determined by dividing $1,000 by 83% of the Closing Price of the Company's Common Stock. The term "Closing Price" was defined as the average closing bid price of the Company's Common Stock over the five-day trading period ending on the day prior to the conversion of the Preferred Stock. All outstanding shares of the Series A Preferred Stock have since been converted into 632,041 shares of the Company's Common Stock. The shares issued upon the conversion of the Series A Preferred Stock were offered for public sale by means of a separate Registration Statement. See "Dilution and Comparative Share Data" for information concerning the Company's Series B and Series C Preferred Stock. Publicly Traded Warrants In connection with the Company's February, 1992 public offering, the Company issued 5,175,000 Warrants. Every five Warrants entitle the holder to purchase one share of the Company's Common Stock at a price of $6.00 per share prior to February 7, 1998. The Warrants were issued pursuant to the terms of a Warrant Agreement between the Company and American Securities Transfer & Trust, Inc. (the "Warrant Agent"). The Company has authorized and reserved for issuance l,035,000 shares of Common Stock issuable upon the exercise of the Warrants. The Company, upon 30-days notice, may accelerate the expiration date of the Warrants, provided, however, that at the time the Company gives such notice of acceleration (1) the Company has in effect a current registration statement covering the shares of Common Stock issuable upon the exercise of the Warrants and (2) at any time during the 30 day period preceding such notice, the average closing bid price of the Company's Common Stock has been at least 20% higher than the Warrant exercise price for 15 consecutive trading days. If the expiration date is accelerated, all Warrants not exercised within the 30-day period will expire. Other provisions of the Warrants are set forth below. This information is subject to the provisions of the Warrant Certificate representing the Warrants. -22- 1. Holders of the Warrants may sell the Warrants rather than exercise them. However, there can be no assurance that a market will continue as to the Warrants. 2. Unless exercised within the time provided for exercise, the Warrants will automatically expire. 3. The exercise price of the Warrants may not be increased during the term of the Warrants, but the exercise price may be decreased at the discretion of the Company's Board of Directors by giving each Warrant holder notice of such decrease. The exercise period for the Warrants may be extended by the Company's Board of Directors giving notice of such extension to each Warrant holder of record. 4. There is no minimum number of shares which must be purchased upon exercise of the Warrants. 5. The holders of the Warrants in certain instances are protected against dilution of their interests represented by the underlying shares of Common Stock upon the occurrence of stock dividends, stock splits, reclassifications, and mergers. 6. The holders of the Warrants have no voting power and are not entitled to dividends. In the event of a liquidation, dissolution, or winding up of the Company, holders of the Warrants will not be entitled to participate in the distribution of the Company's assets. Series A Warrants Each Series A Warrant entitles the holder to purchase one share of the Company's Common Stock at a price of $18.00 per share at any time prior to February 7, 2000. The Company, upon 30-days notice, may accelerate the expiration date of the Series A Warrants, provided, however, that at the time the Company gives such notice of acceleration (1) the Company has in effect a current registration statement covering the shares of Common Stock issuable upon the exercise of the Series A Warrants and (2) at any time during the 30 day period preceding such notice, the average closing bid price of the Company's Common Stock has been at least 20% higher than the warrant exercise price for 15 consecutive trading days. If the expiration date is accelerated, all Series A Warrants not exercised within the 30-day period will expire. Other provisions of the Series A Warrants are set forth below. This information is subject to the provisions of the Warrant Certificate representing the Warrants. 1. Holders of the Series A Warrants may sell the Warrants rather than exercise them. However, there can be no assurance that a market will develop or continue as to the Series A Warrants. 2. Unless exercised within the time provided for exercise, the Series A Warrants will automatically expire. -23- 3. The exercise price of the Series A Warrants may not be increased during the term of the Series A Warrants, but the exercise price may be decreased at the discretion of the Company's Board of Directors by giving each Series A Warrant holder notice of such decrease. The exercise period for the Series A Warrants may be extended by the Company's Board of Directors giving notice of such extension to each Series A Warrant holder of record. 4. There is no minimum number of shares which must be purchased upon exercise of the Series A Warrants. 5. The holders of the Series A Warrants in certain instances are protected against dilution of their interests represented by the underlying shares of Common Stock upon the occurrence of stock dividends, stock splits, reclassifications, and mergers. 6. The holders of the Series A Warrants have no voting power and are not entitled to dividends. In the event of a liquidation, dissolution, or winding up of the Company, holders of the Series A Warrants will not be entitled to participate in the distribution of the Company's assets. Transfer Agent American Securities Transfer & Trust, Inc., of Denver, Colorado, is the transfer agent and registrar for the Company's Common Stock and Warrants. EXPERTS The financial statements incorporated by reference in this prospectus by reference from the Company's Annual Report on Form l0-K have been audited by Deloitte & Touche LLP, independent auditors, as stated in their report which is incorporated herein, and have been so incorporated in reliance upon the report of such firm given upon their authority as experts in accounting and auditing. INDEMNIFICATION The Company's Bylaws authorize indemnification of a director, officer, employee or agent of the Company against expenses incurred by him in connection with any action, suit, or proceeding to which he is named a party by reason of his having acted or served in such capacity, except for liabilities arising from his own misconduct or negligence in performance of his duty. In addition, even a director, officer, employee, or agent of the Company who was found liable for misconduct or negligence in the performance of his duty may obtain such indemnification if, in view of all the circumstances in the case, a court of competent jurisdiction determines such person is fairly and reasonably entitled to indemnification. Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers, or persons controlling the Company pursuant to the foregoing provisions, the Company has been informed that in the opinion of the Securities and Exchange Commission, such indemnification is against public policy as expressed in the Act and is therefore unenforceable. -24- ADDITIONAL INFORMATION The Company has filed with the Securities and Exchange Commission, 450 5th Street, N.W., Washington, D.C. 20001, a Registration Statement under the Securities Act of l933, as amended, with respect to the securities offered hereby. This Prospectus does not contain all of the information set forth in the Registration Statement. For further information with respect to the Company and such securities, reference is made to the Registration Statement and to the Exhibits filed therewith. Statements contained in this Prospectus as to the contents of any contract or other documents are summaries which are not necessarily complete, and in each instance reference is made to the copy of such contract or other document filed as an Exhibit to the Registration Statement, each such statement being qualified in all respects by such reference. Copies of each document may be inspected at the Commission's offices at 450 Fifth Street, N.W., Washington, D.C., 20549, at the Northeast Regional Office, 7 World Trade Center, 13th Floor, New York, New York 10048 and the Midwest Regional Office, Suite 1400, 500 West Madison Street, Chicago, Illinois 60681-2511. This Registration Statement and the related exhibits may also be inspected at the Internet Web Site maintained by the Securities and Exchange Commission at www.sec.gov. Copies may be obtained at the Washington, D.C. office upon payment of the charges prescribed by the Commission. -25- No dealer, salesman or other person has been authorized to give any information or to make any representations, other than those contained in this Prospectus. Any information or representation not contained in this Prospectus must not be relied upon as having been authorized by the Company. This Prospectus does not constitute an offer to sell, or a solicitation of an offer to buy, the securities offered hereby in any state or other jurisdiction to any person to whom it is unlawful to make such offer or solicitation. Neither the delivery of this Prospectus nor any sale made hereunder shall, under any circumstances, create an implication that there has been no change in the affairs of the Company since the date hereof. TABLE OF CONTENTS Page Prospectus Summary ........................................... 5 Risk Factors ................................................. 10 Use of Proceeds............................................... 14 Dilution and Comparative Share Data .......................... 14 Market for the Company's Common Stock......................... 18 Plan of Distribution ......................................... 17 Description of Securities .................................... 18 Experts ...................................................... 18 Indemnification .............................................. 18 Additional Information ....................................... 18 CEL-SCI CORPORATION PROSPECTUS November 14, 1997 -----END PRIVACY-ENHANCED MESSAGE-----